drugset / Trial / NCT03257033
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Timeline
- Start
- 2018-03-12
- Primary completion
- 2026-06
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Other |
| Comparator | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |